Key result
Mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors offer important cardio-renal protective effects for managing patients with chronic kidney disease.
Why the study?
CKD patients complicated by cardiovascular disease and heart failure are increasing, raising the importance of comprehensive management with novel agents like MRAs and ARNIs.
Does the use of mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and their combination with SGLT2 inhibitors improve cardiovascular and renal outcomes in patients with chronic kidney disease and heart failure?
Does the use of mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors, and their combination with SGLT2 inhibitors improve cardiovascular and renal outcomes in patients with chronic kidney disease and heart failure?
Novel therapies including MR antagonists, ARNI, and SGLT2 inhibitors, particularly in combination, offer significant cardio-kidney protective effects for patients with complex comorbidities like CKD, heart failure, and type 2 diabetes.
Answers are grounded in this paper and cite their sources.
May support cardio-renal protection with MRAs and ARNIs in CKD; leaves open optimal SGLT2 inhibitor combinations pending trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kouichi Tamura (2023) studied this question. Mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors offer important cardio-renal protective effects for managing patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: